Official Site for VAQTA® (Hepatitis A Vaccine, Inactivated)
VAQTA® (Hepatitis A Vaccine, Inactivated) is indicated for the prevention of disease caused by hepatitis A virus (HAV) in persons 12 months of age and older. The primary dose should be given at least 2 weeks prior to expected exposure to HAV.
VAQTA® (Hepatitis A Vaccine, Inactivated) for Adult Patients
VAQTA® (Hepatitis A Vaccine, Inactivated) is indicated for the prevention of disease caused by hepatitis A virus (HAV) in persons 12 months of age and older. The primary dose should be given at least 2 weeks prior to expected exposure to HAV.
VAQTA | FDA - U.S. Food and Drug Administration
2020年10月26日 · Tradename: VAQTA Manufacturer: Merck Sharp & Dohme Corp. Indications: For the prevention of disease cause by hepatitis A virus (HAV) in persons 12 months of age and older. Product Information
Hepatitis A Vaccine Administration - CDC
2024年1月11日 · The United States Food and Drug Administration (FDA) has licensed two single-antigen hepatitis A vaccines (Havrix and Vaqta) and one combination vaccine for protection against both hepatitis A and hepatitis B (Twinrix) for use in the US.
• VAQTA is a vaccine that helps prevent Hepatitis A. Hepatitis A is an infection of the liver. • It is a vaccine for people 12 months of age and older. What do you need to know about VAQTA? •...
VAQTA® [Hepatitis A Vaccine, Inactivated] is indicated for the prevention of disease caused by hepatitis A virus (HAV) in persons 12 months of age and older. The primary dose should be given at...
Vaqta: Package Insert / Prescribing Info - Drugs.com
2024年11月20日 · VAQTA is an inactivated whole virus vaccine derived from hepatitis A virus grown in cell culture in human MRC-5 diploid fibroblasts. It contains inactivated virus of a strain which was originally derived by further serial passage of a proven attenuated strain.